Regeneron Pharmaceuticals (REGN) to Release Earnings on Friday

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) is projected to post its Q2 2025 quarterly earnings results before the market opens on Friday, August 1st. Analysts expect Regeneron Pharmaceuticals to post earnings of $8.53 per share and revenue of $3.30 billion for the quarter.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 earnings per share for the quarter, missing analysts' consensus estimates of $8.83 by ($0.61). The business had revenue of $3.03 billion for the quarter, compared to the consensus estimate of $3.40 billion. Regeneron Pharmaceuticals had a return on equity of 15.27% and a net margin of 31.94%. The company's quarterly revenue was down 3.7% on a year-over-year basis. During the same period last year, the firm earned $9.55 earnings per share. On average, analysts expect Regeneron Pharmaceuticals to post $36 EPS for the current fiscal year and $38 EPS for the next fiscal year.

Regeneron Pharmaceuticals Trading Down 0.3%

NASDAQ REGN traded down $1.54 during trading on Friday, reaching $563.10. 755,785 shares of the stock traded hands, compared to its average volume of 906,903. The firm has a market cap of $60.79 billion, a price-to-earnings ratio of 14.34, a price-to-earnings-growth ratio of 2.11 and a beta of 0.33. The stock's 50-day moving average price is $543.18 and its 200 day moving average price is $610.72. The company has a quick ratio of 4.03, a current ratio of 4.93 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals has a fifty-two week low of $476.49 and a fifty-two week high of $1,211.20.

Regeneron Pharmaceuticals Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, June 6th. Investors of record on Tuesday, May 20th were issued a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a yield of 0.63%. The ex-dividend date of this dividend was Tuesday, May 20th. Regeneron Pharmaceuticals's dividend payout ratio is currently 8.96%.

Analyst Ratings Changes

A number of research analysts recently issued reports on the stock. Citigroup decreased their price objective on shares of Regeneron Pharmaceuticals from $700.00 to $650.00 and set a "buy" rating for the company in a report on Monday, June 2nd. UBS Group boosted their price objective on shares of Regeneron Pharmaceuticals from $560.00 to $584.00 and gave the company a "neutral" rating in a report on Friday, July 11th. Argus cut shares of Regeneron Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Monday, June 30th. Wall Street Zen cut shares of Regeneron Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Thursday, May 1st. Finally, Robert W. Baird reduced their price target on shares of Regeneron Pharmaceuticals from $759.00 to $652.00 and set a "neutral" rating for the company in a report on Friday, April 25th. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating, sixteen have given a buy rating and two have issued a strong buy rating to the company's stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $837.61.

Hedge Funds Weigh In On Regeneron Pharmaceuticals

A hedge fund recently bought a new stake in Regeneron Pharmaceuticals stock. Dynamic Technology Lab Private Ltd acquired a new position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) during the first quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 357 shares of the biopharmaceutical company's stock, valued at approximately $226,000. 83.31% of the stock is owned by hedge funds and other institutional investors.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.